There is strong evidence that epidermal growth factor receptor (EGFR) plays a role in tumor progression. A new study by Spano et al. has examined the relationship between EGFR expression, clinicohistological characteristics and survival in patients with colorectal cancer. Although EFGR was not shown...
Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Interleukin-4 receptor (IL-4R) and Epidermal Growth Factor receptor (EGFR) were assessed as factors associated with adenoma-carcinoma progression in colore... L,Kaklamanis,K,... - 《British Journal of Ca...
在KRAS野生型结直肠癌患者进展后应用西妥昔单抗(Cetuximab After Progression in KRAS wIld type colorectal cancer-Gruppo Oncologico dell' Italia Meridionale,CAPRI-GOIM)研究中进行了一项扩展性转化研究项目,其目的是通过评估液体活检的作用及其...
1360 have rewired interactions, SNVs affect 1.6% of nodes and 2.6% of rewired interactions. These data suggest that structural variants, SNVs and CNV-driven changes in gene/protein expression have limited impact on EGFRNet rewiring. Nonetheless, we cannot rule out that these or other genetic di...
current status egfr-targeted therapies in colorectal cancer Epidermal growth factor receptors (EGFRs) play an important role in the development of the skin and up-regulation of these receptors is associated with man... WD Buie,MJ Overman,PM Hoff,... 被引量: 0发表: 2019年 Primary and acquir...
Cetuximab has been shown to be active as well as single agent as in combination with irinotecan in patients with chemorefractory metastatic colorectal cancer [1]. Panitumumab has been shown to be active as single agent in chemorefractory mCRC [2]. The activity of cetuximab in combination with ...
In colorectal cancer, epidermal growth factor receptor (EGFR) expression is reported in 8-100% of the cases examined and there has been no clear association between EGFR expression and prognosis, or response to EGFR inhibitors. In this retrospective study, 87 archival specimens from node positive ...
[6] Fukuoka S, et al. Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). J Clin Oncol. 2020 Jun 20;38(18):2053-2061. doi: 10.1200/JCO.19.03296. Epub 2020 Apr 28. ...
Directly or indirectly, EGFR has been associated for years with worse prognosis and more aggressive tumors in some of the most lethal cancers worldwide, such as breast, head and neck, lung, prostate and colorectal cancer (Baraibar et al., 2020; Khan et al., 2019; Kyriakopoulou et al.,...
British Journal of Cancer (2011) 105, 255 – 262 & 2011 Cancer Research UK All rights reserved 0007 – 0920/11 www.bjcancer.com EGFR gene copy number assessment from areas with highest EGFR expression predicts response to anti-EGFR therapy in colorectal cancer A A˚ lgars*,1,2, M Lin...